Clinical Trial

A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18 years and older.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-02; most recent amendment 2025-03-11.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-03-11
Trial Details
NCT Number NCT06442241
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Collaborators: Yantai Patronus Biotech Co., Ltd.
Conditions Respiratory Syncytial Virus (RSV), RSV Infection
Enrollment 84 participants
Start Date 2024-07-31
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-13